The board of directors of Heska Corporation (NASDAQ:HSKA) Wednesday unanimously voted the removal of Section 5.7 from the Amended and Restated 1997 Stock Incentive Plan (the Stock Plan).

Additionally, the company's board would remove Section 5.7 from the Amended and Restated 1997 Stock Incentive Plan (the Stock Plan) should the Stock Plan be approved at its 2018 Annual Meeting of Stockholders.

According to the company, it manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products and business is composed of Core Companion Animal Health (CCA) (81%) and Other Vaccines, Pharmaceuticals and Products (OVP) (19%).

CCA includes point of care laboratory testing instruments and supplies under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP includes private label vaccine and pharmaceutical production under third party agreements and channels.